In this review, the potential avenues for miRNA-based therapy of ovarian cancer (OC) will be summa- rized. Mainly, the need for OC research stems from its high relapse rates and its tendency to develop resistance to chemotherapy. This paper reviews various articles which look into miRNA dysregulation as a key contributor to OC genetic mutations. Two types of miRNA, miR-126-3p and miR-9, were found to be downregulated in OC, leading to increased cell proliferation. MiR-214 and miR-150, which are upregulated in OC, led to cancer cell proliferation and an increase in drug resistance. Lastly, let-7a miRNA is expressed differently in OC patients, and its up- or downregulation led to sensitivity to only a particular type of chemotherapy, meaning let-7a can serve as a biomarker for determining the best therapeutic approach. In the future, these miRNA types could be used to craft a vector-based approach to curing OC at the molecular level.